Paper
0
Efficacy of Larotrectinib inTRKFusion–Positive Cancers in Adults and Children
Authors
Alexander Drilon,Theodore Laetsch
Shivaani Kummar,Steven DuBois,Ulrik Lassen,George Demetri,Michael Nathenson,Robert Doebele,Anna Farago,Alberto Pappo,Brian Turpin,Afshin Dowlati,Marcia Brose,Leo Mascarenhas,Noah Federman,Jordan Berlin,Wafik El‐Deiry,Christina Baik,John Deeken,Valentina Boni,Ramamoorthy Nagasubramanian,Matthew Taylor,Erin Rudzinski,Funda Meric‐Bernstam,Davendra Sohal,C. Patrick,Luis Raez,Jaclyn Hechtman,Ryma Benayed,Marc Ladanyi,Brian Tuch,Kevin Ebata,Scott Cruickshank,Nora Ku,Michael Cox,Douglas Hawkins,David Hong
+35 authors
,David HymanPublished
Feb 21, 2018
Show more
Save
Tip0
TipSave
Abstract
Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.